Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions

Biodesix, Inc. (NASDAQ:BDSX) is one of the best oversold growth stocks to invest in now. Canaccord lifted the price target on Biodesix, Inc. (NASDAQ:BDSX) to $22 from $20 on May 5, reiterating a Buy rating on the shares. The firm stated that the price target increase is driven primarily by raised revenue assumptions and operating margin expansion in its 10-year DCF model.

Biodesix, Inc. (BDSX): Among Penny Stocks with Insider Buying in 2025

The rating update came after Biodesix, Inc. reported business and financial results for fiscal Q1 2026 on May 4, reporting that Diagnostic Testing revenue reached $22.3 million in the quarter, representing 37% year-over-year growth. This was attributed to a 29% increase in test volumes to 17,800 and a higher average revenue per test, while the improvement in average revenue per test was primarily driven by expanded payer coverage and enhancements to revenue cycle management.

Biodesix, Inc. further reported that total revenue for fiscal Q1 2026 was $25.6 million, up 42% over the respective prior-year comparable period, with an 84% gross margin.

Biodesix, Inc. is a provider of blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat and VeriStrat, along with six other diagnostic tests, including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test, and the Platelia SARS-CoV-2 test.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Follow Insider Monkey on Google News.